Literature DB >> 22926243

Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D.

Sybille Lorenz1, Christine Petersen, Ulrike Kordaß, Heide Seidel, Martin Zenker, Kerstin Kutsche.   

Abstract

Costello syndrome (CS) is a rare congenital disorder characterized by severe failure to thrive, coarse facial appearance, cardiac and skin abnormalities, developmental delay, intellectual disability, and predisposition to malignancies. Heterozygous de novo germline mutations in the proto-oncogene HRAS cause CS. About 80% of patients share the same mutation resulting in the amino acid change p.G12S and present a relatively homogeneous phenotype. Other less common lesions in HRAS can induce a milder phenotype on the one hand and a more severe phenotype on the other broadening the spectrum of clinical manifestations in CS-affected individuals. We report two new patients with the HRAS p.G12C and p.G12D substitutions and a severe neonatal manifestation causing death at the age of three months and 13 days, respectively. Both patients had particularly severe heart involvement with hypertrophic cardiomyopathy and tachyarrhythmia, generalized edema, and respiratory distress. In one case, hypertrophic cardiomyopathy was already noted prenatally. These cases together with other individuals harboring the rare HRAS mutations p.G12C, p.G12V, p.G12D, and p.G12E provide further evidence for a genotype-phenotype correlation that could be of importance for counseling and medical management.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926243     DOI: 10.1016/j.ejmg.2012.07.007

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  11 in total

1.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

2.  Respiratory system involvement in Costello syndrome.

Authors:  Natalia Gomez-Ospina; Christin Kuo; Amitha Lakshmi Ananth; Angela Myers; Marie-Luise Brennan; David A Stevenson; Jonathan A Bernstein; Louanne Hudgins
Journal:  Am J Med Genet A       Date:  2016-04-22       Impact factor: 2.802

3.  Genotype and phenotype spectrum of NRAS germline variants.

Authors:  Franziska Altmüller; Christina Lissewski; Debora Bertola; Elisabetta Flex; Zornitza Stark; Stephanie Spranger; Gareth Baynam; Michelle Buscarilli; Sarah Dyack; Jane Gillis; Helger G Yntema; Francesca Pantaleoni; Rosa LE van Loon; Sara MacKay; Kym Mina; Ina Schanze; Tiong Yang Tan; Maie Walsh; Susan M White; Marena R Niewisch; Sixto García-Miñaúr; Diego Plaza; Mohammad Reza Ahmadian; Hélène Cavé; Marco Tartaglia; Martin Zenker
Journal:  Eur J Hum Genet       Date:  2017-05-03       Impact factor: 4.246

4.  Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline.

Authors:  Eleni Giannoulatou; Gilean McVean; Indira B Taylor; Simon J McGowan; Geoffrey J Maher; Zamin Iqbal; Susanne P Pfeifer; Isaac Turner; Emma M M Burkitt Wright; Jennifer Shorto; Aysha Itani; Karen Turner; Lorna Gregory; David Buck; Ewa Rajpert-De Meyts; Leendert H J Looijenga; Bronwyn Kerr; Andrew O M Wilkie; Anne Goriely
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-20       Impact factor: 11.205

5.  Early-lethal Costello syndrome due to rare HRAS Tandem Base substitution (c.35_36GC>AA; p.G12E)-associated pulmonary vascular disease.

Authors:  K Nicole Weaver; Dehua Wang; James Cnota; Nicholas Gardner; Deborah Stabley; Katia Sol-Church; Karen W Gripp; David P Witte; Kevin E Bove; Robert J Hopkin
Journal:  Pediatr Dev Pathol       Date:  2014-08-18

Review 6.  A system-based approach to the genetic etiologies of non-immune hydrops fetalis.

Authors:  Anne H Mardy; Shilpa P Chetty; Mary E Norton; Teresa N Sparks
Journal:  Prenat Diagn       Date:  2019-06-26       Impact factor: 3.050

7.  Phenotypic spectrum of Costello syndrome individuals harboring the rare HRAS mutation p.Gly13Asp.

Authors:  Débora Bertola; Michelle Buscarilli; Deborah L Stabley; Laura Baker; Daniel Doyle; Dennis W Bartholomew; Katia Sol-Church; Karen W Gripp
Journal:  Am J Med Genet A       Date:  2017-04-03       Impact factor: 2.802

Review 8.  Costello syndrome with special cutaneous manifestations and HRAS G12D mutation: A case report and literature review.

Authors:  Wen Qian; Meijie Zhang; Hequn Huang; Yihe Chen; Gajin Park; Ni Zeng; Yueyue Li; Qian Lu; Dan Luo
Journal:  Mol Genet Genomic Med       Date:  2021-05-01       Impact factor: 2.183

Review 9.  Craniofacial and cutaneous findings in Noonan, Costello and LEOPARD syndromes.

Authors:  Rafał Pokrowiecki; Piotr Chomik; Maciej Borowiec; Krzysztof Dowgierd; Anna Starzyńska
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

10.  The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.

Authors:  Anne-Mette Hartung; Jeff Swensen; Inaki E Uriz; Morten Lapin; Karen Kristjansdottir; Ulrika S S Petersen; Jeanne Mari V Bang; Barbara Guerra; Henriette Skovgaard Andersen; Steven F Dobrowolski; John C Carey; Ping Yu; Cecily Vaughn; Amy Calhoun; Martin R Larsen; Lars Dyrskjøt; David A Stevenson; Brage S Andresen
Journal:  PLoS Genet       Date:  2016-05-19       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.